Loading
A phase 1/2 trial of STI-6129 in multiple myeloma, run by Zhejiang ACEA Pharmaceutical Co. Ltd., now recruiting.
Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT05565807 by Zhejiang ACEA Pharmaceutical Co. Ltd., with 84 participants planned, started 2023-02-09 and due to reach its primary completion in 2026-12-31. Interventions recorded: STI-6129. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares STI-6129, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.